title: Cellular cancer vaccine induces delayed-type hypersensitivity reaction and augments antibody response to tumor-associated carbohydrate antigens (sialyl Le(a), sialyl Le(x), GD3 and GM2) better than soluble lysate cancer vaccine.
abstract: Allogenic whole cell and lysate cancer vaccines are associated with very different clinical outcome, which could be due to different immune responses to critical tumor-associated antigens. We used a guinea pig model to evaluate the immune responses to melanoma-associated carbohydrate antigens administered in whole cell and soluble lysate vaccines produced from the same cell lines and administered with or without Bacille Calmette-Guerin (BCG). Animals immunized with whole cell vaccine developed a significantly higher delayed-type hypersensitivity (DTH) reaction. The IgG response to all tumor-associated carbohydrate antigens except GD2 was significantly higher in animals immunized with whole cell vaccine than lysate vaccine. This study indicates that whole cell vaccine is superior to soluble or lysate vaccine because it induces a better immune response against cell-surface antigens. The addition of BCG significantly increased the antibody response, suggesting that an exogenous adjuvant may immunopotentiate antigens better in the presence of an intact cell membrane.
authors.affiliation: Laboratory of Glycolipid Immunotherapy, John Wayne Cancer Institute at Saint John's Hospital, Santa Monica, CA, USA.
authors.forename: M H
authors.initials: MH
authors.lastname: Ravindranath
authors.forename: P M
authors.initials: PM
authors.lastname: Bauer
authors.forename: A A
authors.initials: AA
authors.lastname: Amiri
authors.forename: S M
authors.initials: SM
authors.lastname: Miri
authors.forename: M C
authors.initials: MC
authors.lastname: Kelley
authors.forename: R C
authors.initials: RC
authors.lastname: Jones
authors.forename: D L
authors.initials: DL
authors.lastname: Morton
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D000912:Antibodies, Neoplasm / Q000096:biosynthesis*; D000954:Antigens, Surface / Q000276:immunology; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000276:immunology*; D001500:BCG Vaccine; D019496:Cancer Vaccines / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005732:Gangliosides / Q000494:pharmacology; D006168:Guinea Pigs; D006968:Hypersensitivity, Delayed / Q000276:immunology*; D007074:Immunoglobulin G / Q000276:immunology; D008545:Melanoma / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000954:Antigens, Surface; D015295:Antigens, Tumor-Associated, Carbohydrate; D001500:BCG Vaccine; D019496:Cancer Vaccines; D005732:Gangliosides; D007074:Immunoglobulin G